Drugs / CBP-201
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05917782 | Jul → Oct 2023 | — | Connect Biopharm LLC | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary | ||||||
| Phase 2 | NCT05905133 | Jul 2023 → Jun 2024 | atopic eczema | Connect Biopharm LLC | Unknown | No outcome recorded |
| Phase 2 | NCT05017480 | Aug 2021 → Dec 2022 | atopic eczema | Connect Biopharm LLC | Completed | No outcome recorded |
| Phase 2 | NCT04783389 | Jun 2021 → Apr 2022 | chronic rhinosinusitis | Connect Biopharm LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04773678 | May 2021 → Aug 2023 | asthma | Connect Biopharm LLC | Completed | Met primary |
| Phase 2 | NCT04444752 | Jul 2020 → Jul 2021 | atopic eczema | Connect Biopharm LLC | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05614817 | Dec 2022 → Aug 2024 | atopic eczema | Connect Biopharm LLC | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06701149 Comparator | Nov 2024 → May 2025 | — | Simcere Pharmaceutical Co., Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-30 | Connect Biopharm LLC | Results Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD connectbiopharma.com ↗
Mean FEV 1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients |
| 2025-07-09 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory NDA of Rademikibart, Jointly Developed by Simcere and Connect Biopharma for the Treatment of Atopic Dermatitis Accepted by NMPA simcere.com ↗
On July 08, 2025, the new drug application (NDA) of the innovative drug Rademikibart, jointly developed by the Simcere （2096.HK） and Connect Biopharma, was accepted by the National Medical Products Administration (NMPA) for the treatment of atopic dermatitis. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-30 | Connect Biopharm LLC | Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD connectbiopharma.com ↗ |
| 2025-07-09 | Jiangsu Simcere Pharmaceutical Co., Ltd. | NDA of Rademikibart, Jointly Developed by Simcere and Connect Biopharma for the Treatment of Atopic Dermatitis Accepted by NMPA simcere.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBP-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05905133 ↗ |
| Route | Subcutaneous | “CBP-201 is administered as a subcutaneous (SC) injection.” NCT04444752 ↗ |